CAMBRIDGE, Mass.--(BUSINESS WIRE)--Glympse Bio, Inc., a life science company developing in vivo activity sensors to transform disease detection, monitoring and drug response, announced today that it has appointed Wendy Winckler, Ph.D., as Chief Scientific Officer. Dr. Winckler, whose expertise includes operational, scientific, technological and clinical leadership, will help advance the company’s novel technology into the clinic.
“We are delighted to have Wendy join our leadership team at this important time,” said Caroline J Loew, President and CEO of Glympse. “Her deep commitment to science, engineering and medicine, combined with her clinical expertise and most recent focus on next generation diagnostics, will be a strong asset to Glympse as we move our technology forward into the clinic.”
Dr. Winckler commented, “I am thrilled to be joining Glympse at this exciting stage for the company. I view this as a wonderful opportunity to participate in a disruptive moment for patient care, and I look forward to helping advance the company’s development pipeline.”
Winckler joins Glympse from the Novartis Institutes for Biomedical Research (NIBR), where she was Executive Director of Next Generation Diagnostics. In that role, she built a department from the ground up, including creation of the strategy and the establishment of the laboratory and analytic capabilities. Previously she worked at the Broad Institute of MIT and Harvard, and before that the Dana Farber Cancer Institute.
Winckler holds a Doctor of Philosophy in Genetics degree from Harvard University and a Bachelor of Science in Microbiology and Molecular Genetics from the University of California, Los Angeles. She is the recipient of a number of National Institutes of Health (NIH) awards, and has authored numerous high-impact scientific publications.
Glympse, a spin-out from the laboratory of Sangeeta Bhatia, M.D., Ph.D. at the Massachusetts Institute of Technology, has developed a novel platform of highly tunable bioengineered activity sensors to query the body for disease status and report out clinically relevant insights rapidly and noninvasively. In October 2018, the company announced a $22 million Series A financing round to advance its lead indication targeting non-alcoholic steatohepatitis (NASH) - a growing pandemic that causes fibrosis and scarring of the liver – believed to afflict more than 100 million people worldwide and 15 million in the United States alone. The Company’s development pipeline features programs in a variety of cancers, immune and infectious diseases.
ABOUT GLYMPSE BIO, INC.
Glympse Bio is pioneering an in
vivo sensing technology dedicated to transforming disease
monitoring. The company has built a product engine enabling rapid
development of tunable and bioengineered activity sensors for multiple
indications including fibrosis, cancer, immunology and infectious
diseases. The technology has been validated in 10 different diseases
using multiple delivery methods and a broad range of analytical
readouts. Glympse aims to improve healthcare globally by serving the
needs of patients, clinicians, researchers, drug developers, and payors
to help advance the science and our understanding of human diseases. The
company is based at the Lab Central incubator in Cambridge, MA. For more
information, please visit http://www.glympsebio.com.
